Chemours short interest steady as analysts keep cutting targets

CC enters its November 5 earnings window with short interest holding near a month-long high, a stock still struggling to find footing after a brutal August, and a Street that has spent the past two months doing little but reducing price targets.

The short position has been essentially stable this week. Short interest edged up just 0.14% over the past seven days to 10.5% of the free float, around 15.7 million shares. That flatness follows a sharper build in late September, when shorts jumped roughly 900,000 shares in a single session around September 22 to 23. The monthly gain remains 18%, so the directional trend is still bearish, but momentum has slowed. The lending market gives no sign of stress. Availability is running at roughly 1,638% relative to short interest, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow at 0.52% is low by any measure, up about 4% on the week but still barely registering. The ORTEX short score has crept to 55.0, its highest reading in the 10-day window shown, though the move is gradual rather than alarming. Options positioning backs up the cautious read: the put/call ratio at 0.53 is above its 20-day average of 0.45 but sits well below the 52-week high of 0.57 hit last week. The setup is defensive, not panicked.

Where the story has become more pointed is on the Street. Analysts have cut targets repeatedly and without changing their underlying ratings, a pattern that signals reluctant holders rather than genuine conviction either way. UBS lowered its target from $18 to $16 on October 5, maintaining Neutral, the second time it has cut in two months after downgrading from Buy in August. Mizuho trimmed from $20 to $18 on September 30, keeping Outperform. JP Morgan's August cut, from $22 to $15, was the most aggressive of the cluster. The mean target now sits at $18.33 against a share price of $13.98, implying roughly 31% potential upside on paper. That gap reflects how far the stock has fallen rather than fresh optimism. The bull case rests on Chemours's "Pathway to Thrive" cost programme, which targets more than $250 million in incremental run-rate savings through 2027, and on the expectation of improved TiO2 margins. The bear case points to regulatory pressure on HFCs, new TiO2 capacity coming online, and weak end-market demand in housing and automotive. On factor scores, earnings momentum over 12 months forward ranks in the 82nd percentile, a sign that the forward earnings revision story is improving from a low base. EPS surprise, however, ranks only in the 2nd percentile, which squares with the August quarter, when the stock dropped roughly 15% the day after results.

That earnings reaction history is worth dwelling on. The three most recent prints produced next-day moves of minus 14.7%, minus 14.7%, and minus 15.7%, with five-day moves all falling in the minus 13% to minus 15% range. These were not close calls. The stock's reaction function to earnings has been consistently and heavily negative, which makes the November 5 date one of the most important variables in how shorts and hedgers will behave over the next four weeks. The ORTEX Wikipedia attention signal showed a z-score of 2.05 as of September 23, indicating retail attention running well above the prior 90-day baseline, though this is a sentiment and attention measure rather than a revenue indicator.

On the ownership side, BlackRock remains the largest holder at about 15.5% of shares, and added roughly 897,000 shares in the quarter to September 30. JP Morgan Asset Management added 773,000 shares over the same period. Those are meaningful accumulations against the backdrop of a falling stock. The cluster of insider buying in early August, when the CEO, CFO, a director, and several other insiders all made open-market purchases in the $15 to $16 range within days of the earnings selloff, is worth noting for context. Those trades are now underwater at the current price of $13.98. Among close peers, TROX fell 6.1% on the week and CE dropped 1.1%, while BAS edged up 2.0%, suggesting the chemicals sector is under broad pressure with Chemours broadly in line directionally.

The November 5 print, earnings reaction history, and the continued drip of downward analyst revisions are the three things most worth tracking between now and the close of Q3 reporting.